Rubedo Life Sciences vs Vima Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
$40M Series A. First patient dosed in Phase 1 for RLS-1496 — first GPX4 modulator targeting pathological senescent cells via ferroptosis. Novel senolytic mechanism.
About
Rubedo Life Sciences is a senolytic drug company that has advanced RLS-1496 into Phase 1 clinical trials — the first GPX4 (glutathione peroxidase 4) modulator designed to selectively eliminate pathological senescent cells through ferroptosis, a form of programmed cell death. The company has raised $40 million in Series A financing and dosed its first patient in June 2025, with a systemic formulation entering Phase 1 planned for 2026 that would dramatically broaden its clinical scope.
Raised $100M Series A extended ($60M + $40M add-on after clinical data) from Atlas, Frazier, Access Industries. Only oral drug in development for isolated dystonia. Phase 2 in dystonia and Parkinson's in 2026.
About
Vima Therapeutics is developing VIM0423, the only oral drug in clinical development for isolated dystonia — a movement disorder characterized by involuntary, sustained muscle contractions affecting approximately 160,000 people in the US, with zero FDA-approved oral treatment options. The company raised a $100 million Series A (extended from $60 million to $100 million after positive clinical data) from Atlas Venture, Frazier Life Sciences, and Access Industries. VIM0423 is entering Phase 2 trials in both isolated dystonia and Parkinson's disease tremor in 2026.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.